[EN] SUBSTITUTED TETRAHYDROPYRANS AND METHOD OF USE<br/>[FR] TÉTRAHYDROPYRANNES SUBSTITUÉS ET MÉTHODE D'UTILISATION ASSOCIÉE
申请人:ABBVIE INC
公开号:WO2016069891A1
公开(公告)日:2016-05-06
Compounds of formula (I) and pharmaceutically acceptable salts or radiolabeled forms thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 and m are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
式(I)的化合物及其药学上可接受的盐或放射标记形式,其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12和m如规范中所定义,可用于治疗由囊性纤维化跨膜传导调节蛋白(CFTR)蛋白预防或改善的疾病或疾病。描述了制备这些化合物的方法。还描述了式(I)的化合物的药物组合物,以及使用这些化合物和组合物的方法。